Agios Pharmaceuticals (AGIO) Non Operating Income (2020 - 2026)

Agios Pharmaceuticals has reported Non Operating Income for 7 years, with the latest figure at $119000.0 in Q1 2026.

• For the quarter ending Q1 2026, Non Operating Income fell 90.5% year-over-year to $119000.0; the trailing twelve-month figure through Mar 2026 stood at $822000.0 (down 86.54% YoY), and the FY2025 full-year result was $2.0 million, down 69.85% from the prior year.
• Non Operating Income for Q1 2026 stood at $119000.0, up from $113000.0 in the prior quarter.
• The five-year high for Non Operating Income was $3.0 million in Q1 2022, with the low at $67000.0 in Q3 2025.
• Historically, Non Operating Income has averaged $1.3 million across 5 years, with a median of $1.4 million in 2022.
• Annual changes were most pronounced in 2024 — Non Operating Income surged 37.81% — and 2025, when it tumbled 95.94%.
• Agios Pharmaceuticals' Non Operating Income stood at $1.4 million in 2022, then advanced by 26.23% to $1.7 million in 2023, then retreated by 5.25% to $1.6 million in 2024, then slumped by 93.04% to $113000.0 in 2025, then rose by 5.31% to $119000.0 in 2026.
• The last three Non Operating Income figures came in at $119000.0 (Q1 2026), $113000.0 (Q4 2025), and $67000.0 (Q3 2025), per Business Quant data.